Loncastuximab tesirine, a CD19 ADC, together with Ibrutinib, presented an encouraging ORR of 73.7% (with 45.5% in CR) as salvage therapy for R/R DLBCL in the interim analysis of the actively recruiting phase II LOTIS-3 trial [108]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.